78 Thirdly, the risk of local recurrence declines with age, an effect likely to be enhanced by endocrine therapy.
However, after the peak risk period, the risk of recurrence declines rapidly, and recurrences seldom occur thereafter [ 3, 4].
Others have also reported that while the incidence of true local recurrence declines with time, that of new breast cancers in other areas of the previously treated breast and new contralateral breast cancers increases with time, so that the overall rate of treatable relapse remains constant for over 15 years (Freedman et al, 2005).
They reported that the risk of recurrence declined rapidly after 4 years and no recurrences occurred after 8 years.
Annual costs for patients remaining in the same health state showed high initial costs for contralateral and locoregional recurrence, with low costs in subsequent years, while costs associated with distant recurrence declined at a slower rate and plateaued at 4 5 years post-diagnosis.
Monitoring costs increased by ¥3,744 but recurrence costs declined by ¥46,113 per patient.
No upper urothelial carcinoma recurrence or declined renal function was diagnosed.
An MRI was obtained within 48 hours after surgery; then, follow-up MRI, NCF, ADL, KPS, RPA classification, and toxicity assessments were obtained at months 2, 4, 6, 9, and 12. Patients were followed for 12 months unless there was evidence of treatment failure (eg, local recurrence), neurologic decline because of CNS metastases, withdrawal from the study, or death.
Although the details vary with the different patients, in principle the data illustrate that the imatinib-resistant mutant clone that predominates in initial recurrence of disease declines to undetectable levels when de-selected but can reappear when the therapy, for one reason or another, is changed again.
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting.
Habel LA, Achacoso N, Nekhlyudov L, Haque R, Schnitt S, Collins L, Acton L, Fletcher S, Quesenberry C. Declining recurrence rates among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting (poster presentation).
